Genetics May Shape the Future of GLP-1 Medications

Childhood obesity treatment is entering a new and highly personalized era. As GLP-1 receptor agonists gain traction as effective tools for weight management in adolescents, emerging research suggests that genetics may play a key role in determining who benefits most (and who experiences side effects).

This evolving intersection of obesity medicine and precision health could transform how providers treat pediatric patients. But it also raises important questions about cost, access, and equity.

The rise of GLP-1 medications in pediatric care

GLP-1 (glucagon-like peptide-1) receptor agonists, including semaglutide and liraglutide, have rapidly become a cornerstone of modern obesity treatment. Originally developed for type 2 diabetes, these medications help regulate appetite, slow digestion, and improve blood sugar control. In adolescents with obesity, clinical trials have demonstrated significant reductions in body mass index (BMI), often far exceeding results from lifestyle interventions alone.

A major study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16% reduction in BMI over 68 weeks. These results have fueled growing adoption in pediatric care and prompted updated treatment guidelines from the American Academy of Pediatrics, which now include pharmacotherapy as part of comprehensive obesity management.

While GLP-1 medications have shown impressive results, not all patients respond the same way. Some adolescents lose significant weight, while others see more modest changes, or struggle with side effects like nausea and vomiting. Recent research highlights a possible explanation: genetic variation. Studies suggest that certain genetic differences may influence how the body regulates appetite and metabolism, how strongly GLP-1 receptors respond to medication, and the likelihood and severity of gastrointestinal side effects.

In fact, new findings reported by Reuters indicate that specific genetic markers may be linked to both greater weight loss outcomes and increased side effect risk in patients taking GLP-1 drugs. This opens the door to a more tailored approach, where treatment decisions are guided not just by BMI or medical history, but by a patient’s genetic profile.

What is personalized (precision) medicine?

Personalized medicine, also known as precision medicine, is an approach that uses individual factors like genetics, environment, and lifestyle to guide healthcare decisions. The National Institutes of Health defines precision medicine as a way to “optimize medical care by tailoring it to individual characteristics.”

In the context of pediatric obesity, this could mean identifying which children are most likely to benefit from GLP-1 medications, predicting who may experience side effects before treatment begins, and adjusting dosages or selecting alternative therapies based on genetic insights. This approach has the potential to make treatment more effective, safer, and more efficient.

Potential benefits for pediatric patients

If successfully implemented, genetically guided obesity treatment could offer several advantages:

1. Improved Outcomes. Children could receive medications that are more likely to work for their specific biology, increasing the chances of meaningful weight loss and improved health.
2. Reduced Trial-and-Error. Providers could avoid prescribing medications that are less likely to be effective, saving time and reducing frustration for families.
3. Better Side Effect Management. Identifying genetic risk factors for side effects may help clinicians proactively manage or avoid adverse reactions.
4. More Efficient Use of Healthcare Resources. Targeted treatment could reduce unnecessary costs associated with ineffective therapies.

Ethical and equity considerations

While the promise of personalized medicine is compelling, it also introduces new challenges, particularly around access and equity, such as cost barriers, a risk of widening disparities, and data privacy concerns. Genetic testing can be expensive, and insurance coverage is inconsistent. Combined with the already high cost of GLP-1 medications, this could limit access for many families.

Also, communities already disproportionately affected by childhood obesity, such as low-income and minority populations, may have the least access to advanced testing and treatments. And, the Centers for Disease Control and Prevention continues to report higher obesity rates among underserved populations, making equitable access a critical concern. Plus, genetic testing raises questions about how sensitive health data is stored, shared, and protected (especially for children).

The integration of genetics into pediatric obesity treatment represents a major step toward more individualized, science-driven care. However, experts emphasize that medication, personalized or not, should always be part of a broader, holistic approach.

As research continues, the key challenge will be ensuring that innovation does not outpace accessibility. Personalized treatment has the potential to improve outcomes, but only if it is available to all children who need it.

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Semaglutide Treatment Effect in People With Obesity — STEP TEENS,” American College of Cardiology, 12/20/22
Source: “Genetics may help explain why results from weight-loss jabs vary, say scientists,” The Guardian, 4/6/26
Source: “Researchers move closer to matching patients with GLP-1 drug that works best for them,” Reuters, 11/19/25
Source: “The Promise of Precision Medicine,” NIH, undated
Source: “New CDC Data Show Adult Obesity Prevalence Remains High,” CDC, 9/12/24
Image by Tara Winstead/Pexels

The Rise of GLP-1 Medications in Pediatric Obesity: Breakthrough or Barrier?

Childhood obesity remains one of the most urgent public health challenges in the United States, affecting roughly one in five children and adolescents. According to the Centers for Disease Control and Prevention, the prevalence of obesity among U.S. youth is about 19.7%, with higher rates among certain racial, ethnic, and low-income populations.

While lifestyle interventions, such as improved nutrition, increased physical activity, and behavioral counseling, have long been the foundation of treatment, a new class of medications is rapidly transforming the field: GLP-1 receptor agonists. These drugs are generating both excitement and debate, especially as their use expands into pediatric care.

So, are GLP-1 medications a true breakthrough, or do they risk widening existing gaps in care?

What are GLP-1 medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications that mimic a naturally-occurring hormone involved in regulating appetite, insulin secretion, and digestion. By slowing gastric emptying and increasing satiety, they help reduce food intake and promote weight loss.

Two of the most widely discussed GLP-1 medications are semaglutide and liraglutide. Originally approved for type 2 diabetes, both medications are now FDA-approved for chronic weight management in certain adolescent populations aged 12 and older. Their growing popularity reflects a broader shift toward recognizing obesity as a chronic, biologically complex disease, not simply a result of lifestyle choices.

Clinical trials have demonstrated significant results in adolescents using GLP-1 medications. A landmark study published in The New England Journal of Medicine found that teens treated with semaglutide experienced an average 16.1% reduction in BMI, compared to just 0.6% in the placebo group. Similarly, trials involving liraglutide showed meaningful reductions in BMI and improvements in metabolic health markers.

Beyond weight loss, GLP-1 medications may improve insulin resistance, blood pressure, and lipid profiles (cholesterol levels). These benefits are particularly important given that childhood obesity is strongly linked to long-term risks such as type 2 diabetes, cardiovascular disease, and even certain cancers.

Despite their clinical promise, GLP-1 medications remain out of reach for many families. Without insurance, these drugs can cost $900 to $1,300 per month, a significant financial burden. Even for insured patients, access is often delayed by prior authorization requirements, step therapy protocols, and inconsistent coverage policies.

According to the American Academy of Pediatrics, disparities in access to obesity treatment, including medications, mirror broader inequities in healthcare. Children from underserved communities, who are already at higher risk for obesity, are often the least likely to receive advanced treatments.

Additional barriers include limited availability of pediatric obesity specialists, geographic disparities in care access, and stigma surrounding obesity treatment. This raises a critical concern: Could a breakthrough therapy unintentionally widen health disparities?

While short-term outcomes are encouraging, long-term safety data in pediatric populations is still evolving.

Common side effects include nausea, vomiting, diarrhea, or constipation. In most cases, these symptoms are mild to moderate and improve over time. However, there are still unanswered questions about long-term use in developing bodies, potential impacts on growth and development, weight regain after discontinuation, and more.

Early evidence suggests that stopping GLP-1 therapy often leads to partial or full weight regain, highlighting the chronic nature of obesity and the potential need for ongoing treatment. Experts emphasize that medication should not replace foundational lifestyle interventions but instead serve as part of a comprehensive, multidisciplinary care plan.

The emergence of GLP-1 medications marks a turning point in pediatric obesity treatment. For adolescents who have struggled with traditional approaches, these therapies offer meaningful, evidence-based results, and in many cases, renewed hope. However, their full potential will only be realized if systemic barriers are addressed.

Expanding insurance coverage, improving provider access, and reducing stigma will be essential to ensuring equitable care. As research continues and policies evolve, the challenge is clear: How do we ensure that this medical breakthrough benefits all children, not just a select few?

Your responses and feedback are welcome!

Source: “Once-Weekly Semaglutide in Adolescents with Obesity,” The New England Journal of Medicine, 11/2/22
Source: “Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023,” CDC, 6/5/25
Source: “Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics, February 2023
Source: “New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth,” ICER, 10/23/25
Image by Leeloo The First/Pexels

How Childhood Obesity May Be Reshaping the American Dream

For generations, the idea of the American Dream has rested on a simple promise: Every child has the opportunity to build a better life than their parents. But emerging research from Rutgers suggests that a growing health crisis of childhood obesity may be quietly undermining that promise in ways that extend far beyond physical well-being.

Childhood obesity has long been associated with increased risks of chronic conditions like diabetes, heart disease, and mental health challenges. Now, a new study published in the Journal of Population Economics reveals that its impact may also stretch into lifetime earnings and financial mobility.

According to the research, children who experience obesity are significantly less likely to climb the economic ladder as adults. In fact, their income ranking can fall about 20 percentile points below that of their parents, compared to peers who maintained a healthy weight in childhood.

As study co-author Dr. Yanhong Jin explains,

Childhood obesity isn’t just a health crisis — it is an economic mobility crisis.

The study draws on data from the National Longitudinal Study of Adolescent to Adult Health, a large-scale, long-running dataset that has tracked more than 20,000 Americans from adolescence into adulthood over several decades. This rich dataset allowed researchers to examine not only health outcomes, but also education, income, and even genetic factors tied to body weight.

By incorporating genetic data, the researchers were able to isolate the effects of obesity itself, separate from influences such as family income or neighborhood environment. The findings were striking: Even when controlling for these factors, childhood obesity remained strongly linked to lower economic mobility.

The study highlights several key reasons why children with obesity may face economic disadvantages later in life. One is lower educational attainment. Children with obesity may encounter barriers in school, from absenteeism to social stigma, which can impact academic success.

Then there are ongoing health challenges. Chronic health conditions can limit productivity, career choices, and long-term earning potential. Also, think about the workplace disadvantages. Adults who were obese as children reported higher levels of job discrimination and were more likely to end up in lower-paying occupations.

Together, these factors create a compounding effect that can make it harder to achieve upward mobility.

Where you grow up also matters. The research also found that individuals who experienced childhood obesity were less likely to live in economically thriving neighborhoods as adults. They were more likely to reside in areas with lower average incomes and higher poverty rates, further limiting access to opportunity.

Interestingly, the economic impact of childhood obesity was not evenly distributed. Girls experienced a larger economic penalty than boys. Not surprisingly, children from low-income families were more affected. And those raised in the South and Midwest faced stronger long-term impacts. These disparities suggest that childhood obesity may amplify existing inequalities, making it even harder for vulnerable populations to break cycles of poverty.

Traditionally, efforts to address obesity have focused on treatment, helping people lose weight after the condition develops. But this research points to the importance of early prevention.

Intervening during childhood — before obesity takes hold — could yield benefits that go far beyond improved health. It may also enhance educational outcomes, expand career opportunities, and increase the likelihood of upward mobility.

As co-author Man Zhang notes, tackling childhood obesity isn’t just about reducing healthcare costs. It’s about investing in the future economic potential of the next generation.

This study challenges us to think differently about childhood obesity. It is not only a medical issue or a lifestyle concern — it is also a social and economic one.

As science writer and researcher Sanjana Gajbhiye writes for Earth.com,

Preventing obesity early can improve both health and future opportunities. It can support better education, stronger careers, and higher income levels.

Protecting the promise of the American Dream may require expanding how we view public health challenges and recognizing that the well-being of children today is deeply connected to the economic vitality of tomorrow.

Your responses and feedback are welcome!

Source: “Childhood Obesity Makes It Harder to Climb the Economic Ladder, Study Finds,” Rutgers.edu, 3/18/26
Source: “Childhood obesity may lower a child’s chances of moving up in life,” Earth.com, 3/19/26
Image by Towfiqu barbhuiya/Pexels